Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vertex Prices Telaprevir At $49,200 For Course Of Therapy

This article was originally published in The Pink Sheet Daily

Executive Summary

In addition to setting a premium price over that for Merck's competing boceprevir, Vertex also indicated it still plans to go it alone on U.S. commercialization despite Merck/Roche alliance.

You may also be interested in...



J&J Not Seeking To Undercut Incivek, Victrelis On Olysio’s Pricing

While Olysio will be priced higher than Incivek for the course of therapy, J&J has a broader strategy for use of the second-generation protease inhibitor. Market analysts are skeptical about the drug’s prospects even though it has some clear edges over the first-generation protease inhibitors for hepatitis C.

Price Gap Between Brand And Generic Drugs Widening – Express Scripts

In its inaugural Drug Trends Quarterly, Express Scripts finds that prices for branded pharmaceuticals are growing at a faster pace than the Consumer Price Index and the gap between branded and generic drug prices is at its widest point since the pharmacy benefit manager began calculating price indexes for each in 2008.

Vertex's Cystic Fibrosis Drug Kalydeco Could See Speedy Review

High unmet medical need, a genetically targeted patient population and the drug's biological rationale could combine for a faster-than-six-month approval for the novel, disease-modifying therapy.

Related Content

Topics

UsernamePublicRestriction

Register

PS072278

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel